GLP-2-XTEN Fusion Proteins for Extended Half-Life Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing GLP-2 compositions have short half-lives due to rapid degradation by dipeptidyl peptidase IV, requiring frequent administration and complex manufacturing processes, and alternative modifications like PEGylation and Fc fusion result in inefficiencies and product heterogeneity.
Innovation Solution
Development of GLP-2 fusion proteins with extended recombinant polypeptides (XTEN) that enhance pharmacokinetic properties, such as increased half-life and bioavailability, without using PEG or Fc domains, allowing for less frequent dosing and improved manufacturing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If native GLP-2 is used, then biological activity is maintained, but half-life is short due to rapid degradation by DPP-IV
Solution Approach 1:
The patent modifies the amino acid sequence of GLP-2 by substituting alanine at position 2 with glycine, creating a structural parameter change that prevents DPP-IV recognition and degradation. This sequence modification extends the half-life from minutes to hours while preserving biological activity through the maintained GLP-2 receptor binding capability.
Solution Approach 2:
The patent employs a self-degrading mechanism where the modified GLP-2 analog is designed to be rapidly cleared after serving its therapeutic purpose. The extended half-life allows for controlled degradation timing, enabling the peptide to act as a temporary therapeutic agent that naturally disappears from the system without requiring active removal mechanisms.
2Duration of action of moving object
If PEGylation is used to extend half-life, then pharmacokinetic properties improve, but manufacturing complexity and product heterogeneity increase
Solution Approach 1:
The patent extracts and eliminates the PEGylation step from the manufacturing process entirely. Instead of chemically modifying GLP-2 with polyethylene glycol chains, the invention uses a simple amino acid sequence substitution (Ala2→Gly2) that achieves half-life extension through biological means, thereby removing the complex chemical conjugation step and associated heterogeneity problems.
Solution Approach 2:
The patent changes the molecular structure parameter of GLP-2 by substituting a single amino acid residue, which simplifies the manufacturing process compared to PEGylation. This parameter change (amino acid substitution) can be achieved through standard recombinant DNA technology without requiring complex chemical modification steps, thereby reducing manufacturing complexity while extending half-life.
3Duration of action of moving object
If Fc fusion is used to extend half-life, then pharmacokinetic properties improve, but product heterogeneity and manufacturing inefficiency increase
Solution Approach 1:
The patent extracts and removes the Fc domain fusion step from the manufacturing process. Instead of fusing the GLP-2 peptide with the Fc portion of an antibody, the invention uses a minimal modification approach with a single amino acid substitution that achieves half-life extension without introducing the complexity of protein-protein fusion, thereby maintaining product homogeneity.
Solution Approach 2:
The patent makes a minimal parameter change in the GLP-2 sequence (Ala2→Gly2 substitution) rather than undertaking a major structural modification like Fc fusion. This subtle parameter change extends half-life while preserving the simplicity and homogeneity of the original peptide structure, avoiding the manufacturing precision issues associated with Fc fusion.
4Reliability
If frequent administration is used to maintain therapeutic effect, then therapeutic outcome is achieved, but loss of time and productivity decrease
Solution Approach 1:
The patent changes the pharmacokinetic parameter of GLP-2 by modifying the amino acid sequence to resist DPP-IV degradation. This parameter change extends the half-life from minutes to hours, which directly reduces the frequency of administration required to maintain therapeutic effect, thereby saving time and improving productivity.
Solution Approach 2:
The patent achieves continuous therapeutic action by extending the half-life of GLP-2 through amino acid modification. The modified peptide maintains stable concentrations in the bloodstream for extended periods, providing continuous intestinotrophic effects without requiring frequent dosing interruptions, thereby ensuring continuous useful action with reduced administration frequency.
Data Source
AI summary
The present invention relates to compositions comprising GLP-2 protein or variants thereof linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of GLP-2-related conditions.